TetraLogic appoints Jonathan Lloyd Jones CFO and vice-president
This article was originally published in Scrip
TetraLogic Pharmaceuticals, a biopharmaceutical company developing drugs to treat cancer, has appointed Jonathan Lloyd Jones chief financial officer and vice-president of corporate development. From 2006 to 2010 Mr Lloyd Jones served as vice-president of finance at TransMolecular, and prior to that he was a senior director of corporate development at Genzyme.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.